The Latest Breaking News from Moderna

o serious safety concerns have been identified for this new bivalent treatment

Britain became the first country to approve a “bivalent” jab on Monday that directly targets Omicron and the original Covid-19 strain - as 29 million people will initially be invited for the vaccine

Moderna's bivalent vaccine is seen as the "next step" in COVID protection.

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

The prime minister has made claims Australia must be more self-reliant.

The total number of COVID-19 cases identified in Australia since the start of the pandemic is closing in on 10 million.

An Omicron-specific booster vaccination has been approved in the UK

Moderna, Inc (NASDAQ: MRNA) spiked up almost 5% off Friday’s closing price at one point on Monday, before hitting a resistance level at the $179 level and running into a group of sellers. 

Adults over 50 and clinically vulnerable people will be offered the first Covid-19 jab to target two strains of the virus, as part of the UK’s autumn booster programme.